Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BIIB 080

Next Previous
X
Search
Drug Profile

BIIB 080

Alternative Names: BIIB080; IONIS BIIB4RX; IONIS MAPTRx; IONIS-MAPTRX; ISIS 814907

Latest Information Update: 11 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer Biogen; Ionis Pharmaceuticals
  • Class Antidementias; Antisense oligonucleotides; Neuroprotectants
  • Mechanism of Action Gene silencing; Tau protein expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alzheimer's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 07 Nov 2024 Biogen completes enrolment in the phase II CELIA trial in Alzheimer's disease in US, Canada, Japan, Australia, Belgium, Denmark, Germany, Italy, Poland, Spain, Switzerland, United Kingdom (Intrathecal) (NCT05399888)
  • 12 Jun 2024 Biogen plans phase-I pharmacokinetics and safety trial (In volunteers) in June 2024 (Intrathecal, injection) (NCT06454721)
  • 25 Oct 2023 Updated efficacy data from a phase I/II trial in Alzheimer's disease released by Biogen

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top